AP2004003084A0 - 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors - Google Patents

3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Info

Publication number
AP2004003084A0
AP2004003084A0 APAP/P/2004/003084A AP2004003084A AP2004003084A0 AP 2004003084 A0 AP2004003084 A0 AP 2004003084A0 AP 2004003084 A AP2004003084 A AP 2004003084A AP 2004003084 A0 AP2004003084 A0 AP 2004003084A0
Authority
AP
ARIPO
Prior art keywords
imidazolyl
tafia inhibitors
alkoxypropanoic
acids
alky
Prior art date
Application number
APAP/P/2004/003084A
Inventor
Charlotte Moira Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2004003084A0 publication Critical patent/AP2004003084A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alky], C2-6 alkenyl, or C2-6alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each ind pendently selected from hydrogen and optionally substituted C1-6 alky, or R5 t R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.
APAP/P/2004/003084A 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors AP2004003084A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
AP2004003084A0 true AP2004003084A0 (en) 2004-09-30

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003084A AP2004003084A0 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (en) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Use of TAFI inhibitors to enhance myocardial reperfusion and facilitate PCI
EP2361910A4 (en) 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
LT2548871T (en) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cycloalkyl-substituted imidazole derivative
CN102884053B (en) * 2010-03-18 2016-03-02 第一三共株式会社 Cyclopropanecarboxylacid acid derivative
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited Inflammatory intestinal disease therapeutic agent
TWI802591B (en) 2017-09-14 2023-05-21 日商第一三共股份有限公司 Compound having ring structures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
SK1732003A3 (en) * 2000-08-17 2004-08-03 Pfizer Substituted imidazoles as TAFIa inhibitors

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
UY27615A1 (en) 2003-08-29
CN1620291A (en) 2005-05-25
WO2003061652A8 (en) 2004-09-10
CA2472238A1 (en) 2003-07-31
JP2005520811A (en) 2005-07-14
MA27167A1 (en) 2005-01-03
OA12756A (en) 2006-07-03
MXPA04006573A (en) 2004-10-04
NO20043457L (en) 2004-08-19
WO2003061652A1 (en) 2003-07-31
ECSP045200A (en) 2004-08-27
IS7310A (en) 2004-06-14
HRP20040659A2 (en) 2004-10-31
TNSN04121A1 (en) 2006-06-01
AR038197A1 (en) 2005-01-05
KR20040077775A (en) 2004-09-06
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
EA200400716A1 (en) 2004-12-30
EP1467731A1 (en) 2004-10-20
TW200302094A (en) 2003-08-01
BR0307016A (en) 2004-11-03
PE20030929A1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
ATE427300T1 (en) HETEROCYCLIC SUBSTITUTED AMIDES AS CALPAIN INHIBITORS
NO20071642L (en) N-Benzenesulfonyl-substituted anilino-pyrimidine analogs
JO2282B1 (en) Oxazol derivatives
NO20021358D0 (en) Alkylenediamine-substituted heterocycles
EA200601830A1 (en) ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
EA200401381A1 (en) 3-heteroaryl substituted isoxazoline
EA200600509A1 (en) COMPOUNDS OF PYRIMIDOTHIOPHENE
CY1107903T1 (en) ACYLAMINOTHIACEALE PRODUCTS AND THEIR USE AS BETA-AMYLOID INHIBITORS
IS2416B (en) Pyrrolidine dione substituted piperidine thalazone which inhibits PDE4
DK1265606T3 (en) cell adhesion inhibitors
DE502005009201D1 (en) SUBSTITUTED 1-PROPINOYL-PIPERAZINE WITH AFFINITY FOR THE MGLUR5 RECEPTOR FOR TREATING PAIN STATES
IN2012DN00758A (en)
MXPA04005940A (en) 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases.
NO20062272L (en) Methods and Compositions for Selectin Inhibition
AP2004003084A0 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
NO20062348L (en) Methods and Compositions for Selectin Inhibition
NO20063220L (en) Tricyclic imidazopyridines for use as gastric secretion inhibitors
NO20062307L (en) Spirofuropyridinarylderivater
EA200501696A1 (en) NEW TIADIAZINE CONNECTIONS, METHOD OF THEIR RECEPTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
UA86616C2 (en) Novel carboxamides for use as xa inhibitors
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
DE60011300D1 (en) INHIBITORS OF TRYPTASE
DOP2003000564A (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
NO20020886L (en) Novel integrin <alfa> v <beta> 3 inhibitors